ATE366306T1 - Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b - Google Patents

Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Info

Publication number
ATE366306T1
ATE366306T1 AT01973455T AT01973455T ATE366306T1 AT E366306 T1 ATE366306 T1 AT E366306T1 AT 01973455 T AT01973455 T AT 01973455T AT 01973455 T AT01973455 T AT 01973455T AT E366306 T1 ATE366306 T1 AT E366306T1
Authority
AT
Austria
Prior art keywords
rank
kappa
agonists
antagonists
screening methods
Prior art date
Application number
AT01973455T
Other languages
English (en)
Inventor
William Dougall
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE366306T1 publication Critical patent/ATE366306T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01973455T 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b ATE366306T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23515700P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE366306T1 true ATE366306T1 (de) 2007-07-15

Family

ID=22884325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973455T ATE366306T1 (de) 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Country Status (10)

Country Link
US (2) US6884598B2 (de)
EP (1) EP1368464B1 (de)
JP (1) JP4854174B2 (de)
AT (1) ATE366306T1 (de)
AU (2) AU2001293030B2 (de)
CA (1) CA2423052C (de)
DE (2) DE01973455T1 (de)
ES (1) ES2208145T3 (de)
MX (1) MXPA03002443A (de)
WO (1) WO2002024896A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA03010531A (es) * 2001-05-17 2004-07-01 Immunex Corp Uso terapeutico de antagonistas de rank.
EP2087908B1 (de) 2001-06-26 2018-05-30 Amgen Inc. Antikörper gegen opgl
AU2002365426A1 (en) * 2001-10-12 2003-09-02 Barnes-Jewish Hospital Methods for screening osteogenic compounds
US7718776B2 (en) * 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20060040249A1 (en) * 2002-09-26 2006-02-23 Manfred Auer Screening method involving transfected primary cells
US9128090B2 (en) * 2003-08-29 2015-09-08 Janssen Biotech, Inc. Rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
WO2006031718A2 (en) * 2004-09-15 2006-03-23 The Uab Research Foundation Compositions and methods for modulating rank activities
TW200736277A (en) * 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CN101313251A (zh) * 2005-11-23 2008-11-26 纳幕尔杜邦公司 再循环烷烃浸渍液的装置及使用方法
WO2010129710A1 (en) * 2009-05-06 2010-11-11 Emory University Use of rankl to induce differentiation of microfold cells (m cells)
US8598331B2 (en) * 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
JP5867671B2 (ja) * 2011-03-28 2016-02-24 国立大学法人神戸大学 コンディショナルノックアウト動物
CA2854372A1 (en) * 2011-11-07 2013-05-16 Universite Laval Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
US10253330B2 (en) 2013-02-13 2019-04-09 The University Of British Columbia CLDN5 mini-promoters

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127637A (en) * 1872-06-04 Improvement in couplings for divided axles
US13651A (en) * 1855-10-09 Machine for making wire dish-covers
US133170A (en) * 1872-11-19 Improvement in wheelbarrows
US159970A (en) * 1875-02-16 Improvement in sickle-heads for harvesters
US68690A (en) * 1867-09-10 bibge
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB9310194D0 (en) * 1993-05-18 1993-06-30 Millenium Bioligix Inc Assessment of osteoclast activity
JPH0956805A (ja) * 1995-08-24 1997-03-04 Millennium Biologics Inc リン酸カルシウム材の薄膜製造のための改良焼結方法
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
AU5697098A (en) 1996-12-13 1998-07-03 Schering Corporation Mammalian cell surface antigens; related reagents
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
HU229476B1 (en) 1997-04-15 2014-01-28 Daiichi Sankyo Company Antibodies against obm
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
JPH119269A (ja) 1997-06-19 1999-01-19 Kaken Pharmaceut Co Ltd 破骨細胞系細胞
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
KR100671036B1 (ko) 1998-09-15 2007-01-18 파멕사 에이/에스 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
AU5379200A (en) 1999-06-02 2000-12-28 Osteopharm Inc. Bone stimulating factor
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
JP2003505514A (ja) 1999-07-28 2003-02-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞生成を阻害する方法
AU778190B2 (en) 1999-07-28 2004-11-18 Trustees Of The University Of Pennsylvania, The Methods of inhibiting osteoclast activity
AU6946300A (en) 1999-08-30 2001-03-26 Mayo Foundation For Medical Education And Research Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
EP1140136B1 (de) 1999-09-03 2007-05-16 Amgen Inc. Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
EP1087230A1 (de) 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Verfahren zum Nachweis von Verbindungen nützlich in Therapie von Knochenfehlern
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
DK2105449T3 (da) 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
EP1283721A4 (de) 2000-05-26 2004-07-07 Smithkline Beecham Corp Anti-rank-ligand-bindende monoklonale antikörper die nützlich zur behandlung von durch den rank-liganden verursachten krankheiten sind
US20040247596A1 (en) 2000-08-18 2004-12-09 Odgren Paul R. TRANCE regulation of chondrocyte differentiation
EP1458411A4 (de) 2000-08-21 2004-09-22 Smithkline Beecham Corp Anti-rank liganden monoklonale antikörper nützlich zur behandlung von rank liganden vermittelten störungen
WO2002064782A2 (en) 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
EP1385532A4 (de) 2001-03-22 2004-12-15 Barnes Jewish Hospital Stimulation der osteogenese mit rang-ligandenfusionsproteinen
US20030013651A1 (en) 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
JP2005508284A (ja) 2001-03-23 2005-03-31 ジェネンテック・インコーポレーテッド 免疫反応調節のためのｏｐｇリガンドの使用
NZ529314A (en) 2001-05-11 2007-01-26 Res Dev Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
JP2005515752A (ja) 2001-05-18 2005-06-02 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド媒介性障害の治療において有用な抗ｒａｎｋリガンドモノクローナル抗体
EP2087908B1 (de) 2001-06-26 2018-05-30 Amgen Inc. Antikörper gegen opgl

Also Published As

Publication number Publication date
JP4854174B2 (ja) 2012-01-18
WO2002024896A3 (en) 2003-07-10
US7572594B2 (en) 2009-08-11
MXPA03002443A (es) 2004-12-06
US20050196801A1 (en) 2005-09-08
JP2004524812A (ja) 2004-08-19
EP1368464B1 (de) 2007-07-04
DE60129254T2 (de) 2008-03-13
CA2423052A1 (en) 2002-03-28
EP1368464A2 (de) 2003-12-10
WO2002024896A9 (en) 2002-10-03
ES2208145T1 (es) 2004-06-16
AU2001293030B2 (en) 2007-07-19
AU9303001A (en) 2002-04-02
DE60129254D1 (de) 2007-08-16
WO2002024896A2 (en) 2002-03-28
US20020086312A1 (en) 2002-07-04
DE01973455T1 (de) 2004-04-22
ES2208145T3 (es) 2007-12-16
CA2423052C (en) 2011-07-12
US6884598B2 (en) 2005-04-26

Similar Documents

Publication Publication Date Title
ATE366306T1 (de) Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
Witte et al. Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial β-adrenergic signaling
Sawyer et al. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2
She et al. Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells
Gottardi et al. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner
Rolli et al. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells
Nishimura et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60020962D1 (de) Ligande für metabotropische glutamat-rezeptoren
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
ATE358718T1 (de) Integrin antagonisten
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
Lü et al. Syntaxin 1A supports voltage-dependent inhibition of α1B Ca2+ channels by Gβγ in chick sensory neurons
Mahé et al. Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors
MXPA04001287A (es) Ensayo de receptor unido a proteina g.
Kaaijk et al. Expression of CD44 splice variants in human primary brain tumors
ATE132162T1 (de) Humane gammainterferonantagonisten
Pregenzer et al. Characterization of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
Silva et al. Expression and pharmacological characterization of α1-adrenoceptors in rat seminal vesicle
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
ATE279515T1 (de) Pct-65 serotonin rezeptor
Nanda et al. Vinculin regulates assembly of talin: β3 integrin complexes
ATE373717T1 (de) Pde8a und seine verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties